6 Orthobiologic Companies Move Clinical Trials Forward

Multiple orthobiologic companies have engaged in clinical trials in 2019, seeking to demonstrate the efficacy of their cell-based products….

GID BIO completed a multi-site, randomized, placebo-controlled Phase IIb clinical trial with an FDA-approved study design using autologous stromal cells in the treatment of knee osteoarthritis (OA), successfully meeting endpoints and two-year safety results…

Read more via BONEZONE.

✉ RECEIVE OUR NEWSLETTER   
Scroll to Top